About Xyphos
Xyphos is a company based in San Francisco (United States) founded in 2017 by Jim Knighton and David Martin was acquired by Astellas Pharma in December 2019.. The company has 9 employees as of December 31, 2022. Xyphos offers products and services including Immune Cell Therapy. Xyphos operates in a competitive market with competitors including Celgene, GSK, Avidity Biosciences, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 9 as on 31 Dec, 2022
- Founders Jim Knighton, David Martin
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Avidbiotics Corp.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
- Investors
-
Employee Count
9
as on Dec 31, 2022
-
Acquired by
Astellas Pharma
(Dec 26, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xyphos
Xyphos offers a comprehensive portfolio of products and services, including Immune Cell Therapy. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops flexible therapies for controllable immune cells in cancer care
Funding Insights of Xyphos
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Xyphos
Xyphos has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Astellas Pharma. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Generic pharmaceuticals are developed, manufactured, and marketed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Xyphos
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Xyphos
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Xyphos Comparisons
Competitors of Xyphos
Xyphos operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, GSK, Avidity Biosciences, Poseida Therapeutics and Juno Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for cancer and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Xyphos
Frequently Asked Questions about Xyphos
When was Xyphos founded?
Xyphos was founded in 2017.
Where is Xyphos located?
Xyphos is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Xyphos?
Jim Knighton is the current CEO of Xyphos. They have also founded this company.
How many employees does Xyphos have?
As of Dec 31, 2022, the latest employee count at Xyphos is 9.
What does Xyphos do?
The company was founded in 2017 and is based in San Francisco, United States, within the biotechnology sector. Therapies targeting cancers, particularly B cell malignancies, are being developed through convertible CAR-T cell technology. CD19 receptors are targeted, while NKG2D receptors on natural killer cells, T cells, and macrophages are incorporated. Ligands are bound by these receptors, resulting in surface clustering and activation to eliminate stressed cells.
Who are the top competitors of Xyphos?
Xyphos's top competitors include Juno Therapeutics, Sutro Biopharma and Avidity Biosciences.
What products or services does Xyphos offer?
Xyphos offers Immune Cell Therapy.
Who are Xyphos's investors?
Xyphos has 1 investor. Key investors include Astellas Pharma.